The newly published report titled “Global Advanced Therapy Medicinal Products CDMO Market By (Based on product (gene therapy, cell therapy, tissue-engineered and others (combined ATMPs, for example, biodegradable matric or scaffold)), Phase (phases I, II, III, and IV), Indication (oncology, cardiology, central nervous system, musculoskeletal, infectious disease, dermatology, endocrine, metabolic, genetic, immunology & inflammation, ophthalmology, hematology, gastroenterology and others)) – Trends, Industry Competition Analysis, Covid-19 Analysis, Revenue (US$ Billions) and Forecast Till 2034.” of InsightAce Analytic Pvt. Ltd. features detailed industry analysis and an extensive study on the market, exploring its significant factors.
The global Advanced Therapy Medicinal Products CDMO Market Size is valued at 6.7 Billion in 2024 and is predicted to reach 26.6 Billion by the year 2034 at a 15.0% CAGR during the forecast period for 2025-2034.
Request For Free Sample Pages:
https://www.insightaceanalytic.com/request-sample/1369
Advanced Therapeutic Medicinal Products (ATMPs) encompass a specialized category of biopharmaceuticals that includes tissue-engineered products, cell therapies, and gene therapies. The ATMP market is experiencing significant growth, driven by increasing awareness and confidence among researchers regarding the therapeutic potential of these innovations. Additionally, the rising number of clinical trials focused on advanced therapies is further accelerating market expansion.
The demand for ATMPs is surging due to the prevalence of rare and life-threatening diseases, including metabolic disorders and ophthalmic conditions. Increased funding for research and development (R&D) of next-generation therapies is further supporting market growth. Additionally, mesenchymal stem cells (MSCs), a key component of ATMPs, have emerged as a promising treatment option for addressing COVID-19-related complications.
List of Prominent Players in the Advanced Therapy Medicinal Products CDMO Market:
- Celonic
- Bio Elpida
- CGT Catapult
- Rentschler Biopharma SE
- AGC Biologics
- Catalent
- Lonza
- WuXi Advanced Therapies
- BlueReg
- Minaris Regenerative Medicine
- Patheon
Market Dynamics:
Drivers-
The Advanced Therapy Medicinal Products (ATMP) Contract Development and Manufacturing Organization (CDMO) market is experiencing significant growth, primarily driven by the continuous development of innovative therapeutic products. This surge is attributed to the increasing global demand for advanced therapies, particularly in the realms of gene and cell therapy.
Curious about this newest model of the report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1369
Challenges:
Despite the promising growth, the ATMP CDMO market faces notable challenges. The high costs associated with advanced therapy medicinal products pose affordability issues, particularly for uninsured patients. While reimbursement programs in regions like the United States and the European Union cover many products, the financial burden remains substantial for those without insurance coverage.
Regional Trends:
In 2023, North America dominated the ATMP CDMO market, accounting for 49.0% of the global share. This leadership is attributed to increased outsourcing activities and heightened awareness of advanced therapies. The region’s robust research and development initiatives have further solidified its market position.
The Asia-Pacific region is projected to experience the fastest growth rate over the forecast period. This anticipated expansion is driven by the increasing demand for novel ATMPs and rising R&D activities aimed at developing innovative therapies. Countries within this region are enhancing their treatment technologies and expanding outsourcing activities, positioning themselves as significant players in the global ATMP CDMO market.
Recent Developments:
- In November 2020, Catalent will acquire Bone Therapeutics’ cell therapy manufacturing unit. This acquisition has enabled the corporation to broaden its capabilities for pursuing new goods in its industry.
Get Specific Chapter/Information From The Report:
https://www.insightaceanalytic.com/customisation/1369
Segmentation of Advanced Therapy Medicinal Products CDMO Market-
By Product-
- Gene Therapy
- Cell Therapy
- Tissue Engineered
- Others (Combined ATMPs, for example, biodegradable matric or scaffold)
By Phase-
- Phase I
- Phase II
- Phase III
- Phase IV
By Indication
- Oncology
- Cardiology
- Central Nervous System
- Musculoskeletal
- Infectious Disease
- Dermatology
- Endocrine, Metabolic, Genetic
- Immunology & Inflammation
- Ophthalmology
- Hematology
- Gastroenterology
- Others
By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Get more information: @
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.
Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
